-
Home
SOP Information
SOPs and Supporting Information – alphabetic listing
Q to Z
Soft Tissue Sarcoma B009
Rulebase for soft tissue sarcoma
- Inhaling gaseous vinyl chloride
Soft tissue sarcoma - Inhaling gaseous vinyl chloride Factor
Last reviewed for CCPS 20 August 2008.
Investigative Documents
Claimant Report - Inhaling Gaseous Vinyl Chloride [CR9090]
Preliminary questions [22777]
there is some evidence that inhaling gaseous vinyl chloride may be a factor in the development of the condition under consideration.22781 — the veteran has established the causal connection between inhaling gaseous vinyl chloride and VEA service for the clinical onset of soft tissue sarcoma.
22782 — the veteran has established the causal connection between inhaling gaseous vinyl chloride and operational service for the clinical onset of soft tissue sarcoma.
or
22783 — the veteran has established the causal connection between inhaling gaseous vinyl chloride and eligible service for the clinical onset of soft tissue sarcoma.
Clinical onset and operational service [22782]
27347 the veteran inhaled a cumulative dose of at least 200 ppm-years of gaseous vinyl chloride at some time.
the veteran inhaled a cumulative dose of at least 200 ppm-years of gaseous vinyl chloride at least two years before the clinical onset of the condition under consideration. operational service made a material contribution to the veteran inhaling a cumulative dose of at least 200 ppm-years of gaseous vinyl chloride at least two years before the clinical onset of the condition under consideration.Clinical onset and eligible service [22783]
the condition under consideration is an hepatic angiosarcoma. the veteran inhaled a cumulative dose of at least 200 ppm-years of gaseous vinyl chloride at some time. the veteran inhaled a cumulative dose of at least 200 ppm-years of gaseous vinyl chloride at least five years before the clinical onset of the condition under consideration. eligible service made a material contribution to the veteran inhaling a cumulative dose of at least 200 ppm-years of gaseous vinyl chloride at least five years before the clinical onset of the condition under consideration.